Будь ласка, використовуйте цей ідентифікатор, щоб цитувати або посилатися на цей матеріал: http://ir.librarynmu.com/handle/123456789/7596
Повний запис метаданих
Поле DCЗначенняМова
dc.contributor.authorOliynyk, O.-
dc.contributor.authorBarg, W.-
dc.contributor.authorOliynyk, Y.-
dc.contributor.authorDubrov, S.-
dc.contributor.authorGurianov, V.-
dc.contributor.authorRorat, M.-
dc.date.accessioned2023-05-19T07:53:58Z-
dc.date.available2023-05-19T07:53:58Z-
dc.date.issued2022-
dc.identifier.urihttp://ir.librarynmu.com/handle/123456789/7596-
dc.description.abstractAbstract: Tocilizumab (TOC) is presumed to be an effective and safe treatment for severe COVID-19, but its usefulness has not been yet investigated for different SARS-CoV-2 variants. This study aimed to evaluate the influence of TOC on mortality in patients with severe COVID-19 caused by Delta and non-Delta SARS-CoV-2 variants. In a retrospective analysis, we compared the medical records of 78 and 224 patients with severe COVID-19 due to Delta and non-Delta variants, respectively. A total of 30 patients with Delta and 84 with non-Delta variants were treated with TOC in addition to standard therapy. There were no statistically significant differences in mortality rate when comparing Delta vs. non-Delta patients nor when comparing those treated with TOC vs. not treated with TOC in both variants. Using a logistic regression model, in the examined population as a whole, we found an increased (p < 0.05) risk of death as leukocyte and erythrocyte counts decreased and as procalcitonin increased. Increased procalcitonin was significant for mortality in the Delta group, while decreased IL-6, leukocytes, and platelets and increased fibrinogen and procalcitonin were significant in the non-Delta group. Tocilizumab efficacy in severe COVID-19 does not differ between Delta or non-Delta virus variants. The Delta variant of SARS-CoV-2 does not increase mortality when compared to other virus strains.uk_UA
dc.language.isoenuk_UA
dc.publisherJournal of Personalized Medicineuk_UA
dc.subjectmutation; inteleukin-6 inhibitor; ARDSuk_UA
dc.titleLack of Difference in Tocilizumab Efficacy in the Treatment of Severe COVID-19 Caused by Different SARS-CoV-2 Variantsuk_UA
dc.typeArticleuk_UA
Розташовується у зібраннях:Наукові публікації кафедри менеджменту охорони здоров’я післядипломної освіти

Файли цього матеріалу:
Файл Опис РозмірФормат 
Lack of Difference.pdf882,49 kBAdobe PDFПереглянути/Відкрити


Усі матеріали в архіві електронних ресурсів захищені авторським правом, всі права збережені.